Acceleron Pharma Reports Positive Topline Results From PULSAR Trial

By RTTNews Staff Writer ✉ | Published: 1/27/2020 5:24 PM ET

Acceleron Pharma Inc. (XLRN) announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial
hypertension. In the trial, sotatercept showed a statistically significant reduction in pulmonary vascular resistance, the trial's primary endpoint, at week 24 versus placebo.

The company plans to present a detailed review of the topline results from the
PULSAR Phase 2 trial of sotatercept at a medical conference later in the current year.

Shares of Acceleron Pharma Inc. were up nearly 70% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

PDUFA Biotech stocks Chemotherapy COVID19 vaccines heart failure lupus ARS

Biotech Stocks Facing FDA Decision In January 2021

New Drugs Approved In November

PDUFA 2020 Multiple Sclerosis Cystic Fibrosis Edema PAH Sleep wake disorder hereditary angioedema attacks

Biotech Stocks Facing FDA Decision In December 2020

Editors Pick

GE Sues Siemens Energy For Allegedly Stealing Gas-Turbine Trade Secrets

General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains.

Cigarette Health Warnings Effective Date Postponed

Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking.

JPMorgan Chase & Co Q4 Profit Tops Estimates; Managed Net Revenue Up 3%

JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...